Expression of synaptic vesicle protein 2 (SV2) in neuroendocrine tumours of the gastrointestinal tract and pancreas
- 14 November 2001
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 196 (1) , 44-50
- https://doi.org/10.1002/path.1002
Abstract
Identification of neuroendocrine differentiation in tumours has important implications for prognosis and therapy. The aim of the present study was to evaluate monoclonal antibodies against synaptic vesicle protein 2 (SV2) as histopathological markers for neuroendocrine differentiation intumours of the gastroinestinal tract and pancreas. Paraffin blocks from 211 gastrointestinal tumours were examined by immunocytochemistry, using a monoclonal antibody against SV2. Virtually all endocrine tumours of the gastrointestinal tract (11/11 gastric, 53/53 ileal, 16/21 appendiceal, and 22/22 rectal) and pancreas (24/24) were positively labelled. SV2 labelling was also demonstrated in gastrointestinal pacemaker cell tumours (8/8), while adenocarcinomas of the gastrointestinal tract and pancreas were negative, with the exception of occasional adenocarcinomas demonstrating weak SV2 labelling (stomach 1/22, rectum 1/29, and pancreas 0/21). Western blotting of tumour biopsies confirmed expression of SV2 in endocrine tumours of the gastrointestinal tract and pancreas. No relationship was observed between SV2 expression in tumours and hormone production or malignant potential. In conclusion, SV2 is expressed in neuroendocrine tumours of the gastrointestinal tract and pancreas, but not in non‐endocrine tumours. The SV2 monoclonal antibody can therefore be used as a general marker for neuroendocrine differentiation in gastrointestinal and pancreatic tumours. Copyright © 2001 John Wiley & Sons, Ltd.Keywords
Funding Information
- Swedish Cancer Society (3911)
- Swedish MRC (5220)
- I.B. & A. Lundberg Research Foundation
- Assar Gabrielsson Foundation
- Swedish Society of Medicine
- Swedish Society for Medical Research
- Göteborg Medical Society
- King Gustav the Fifth Jubilee Clinic Cancer Fund, Göteborg
- Sahlgrenska University Hospital Research Funds
- Gunvor & Josef Aner Foundation
- Axel Linder Foundation
- Gunnar, Arvid & Elisabet Nilsson Foundation
- Serena Ehrenstrvms Foundation
This publication has 15 references indexed in Scilit:
- Synaptic Vesicle Protein 2, A New Neuroendocrine Cell MarkerThe American Journal of Pathology, 2000
- SV2A and SV2B Function as Redundant Ca2+ Regulators in Neurotransmitter ReleaseNeuron, 1999
- SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein familyNeuroscience, 1999
- Synaptic Vesicle BiogenesisAnnual Review of Cell and Developmental Biology, 1999
- Neuroendocrine cancers of the colon and rectumDiseases of the Colon & Rectum, 1994
- Brain contains two forms of synaptic vesicle protein 2.Proceedings of the National Academy of Sciences, 1993
- SV2, a Brain Synaptic Vesicle Protein Homologous to Bacterial TransportersScience, 1992
- Endocrine secretory granules and neuronal synaptic vesicles have three integral membrane proteins in common.The Journal of cell biology, 1988
- Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells.The Journal of cell biology, 1985
- Specific Endocrine Tissue Marker Defined by a Monoclonal AntibodyScience, 1983